Life Sciences companies focus on developing solutions and innovation through scientific research that covers a wide range of fields, including medicine, agriculture, biology and biotechnology, diagnostics and devices that save and improve the quality of life. The area is responsible for many of the most exciting growth companies developing new game-changing drugs or treatments in healthcare and other industries. To focus on these robust opportunities, here is Equities.com's ongoing coverage of Life Sciences news and education resources for investors that want to know more about this industry.

Latest Articles • Stocks Rally To Slight Losses After Rollercoaster Day • Stocks Tumble After Bernanke’s Comments, FOMC Minutes Catch Wall Street Off-Guard • Dow and S&P 500 Close On Record Highs as Federal Reserve Reiterates Monetary Policy • Q4 Revenue at Medtronic Up 5 Percent, Outlook In Line with Analysts • Wall Street Holds Taps the Breaks Ahead of Federal Reserve Activity • Icahn and Transocean Come to Terms Over Board of Directors, Dividend Payment • Myriad Genetics Gets a Lift from Angelina Jolie Going Public with Double Mastectomy • Agilent Tops Wall Street in Q2, Comes Up Shy on 2013 Guidance • Theravance Spikes on $1 Billion Deal for COPD Treatment • Stocks Make Late Mini-Rally as Wall Street is Up for the Third Straight Week • Tauriga Sciences: Investing in the Breakthroughs of Tomorrow • Henry Schein Reports Revenue Up 9 Percent and Profits Up 8 Percent in Q1 • S&P Capital IQ Focus Stock of the Week: AmerisourceBergen Corp. • Wall Street Edges Modestly Higher Into New Highs • 5 Small-Cap Medical Equipment Stocks That Pay Dividends • S&P Closes Above 16,000 As Dow Briefly Crosses 15,000, Cheered on by Jobs Report • Wall Street Rises on Better Jobless Numbers Sending S&P 500 to a New All-Time High • Wall Street Down on Worries About Slowing Economic Growth • Another Record Close for S&P 500 as Wall Street Gains on Positive Economic News • Pfizer’s Sales Hurt by Generic Competition • Rising Cases of New Bird Flu Highlight Vaccination Debate and Need for New Vaccines • Herbalife Hurdles Expenses from Pyramid Scheme Controversey to Beat on Earnings • Bayer to Spend $1.1 Billion to Broaden Contraception Business • Playing the IPO Market: Knowing Which Indicators To Use for Finding Good IPOs • What Traders Are Watching Now as Earnings Season Rolls On • Apple Now Tops the List of These Dividend Heavy Hitters • 5 Small Cap Dividend Stocks in Healthcare • Playing the IPO Market: Is Fairway Group the Next IPO Disaster? • Stocks Rebound to End Worst Week of 2013 • Vertex Pharmaceuticals Shares Explode on Phase 2 Cystic Fibrosis Study Results • Stocks Dip Again on Spate of Weak Earnings Reports and Economic News • UnitedHealth Group Revenues Climb in Q1, but Profits Drop 14 Percent • 6 Bargain Stocks on the S&P 500 That Are as "Cheap" as Apple • 6 Blue Chips Moonlighting as Growth Stocks • Teva Says Milprosa Vaginal Ring as Effective as Gel in Luteal Phase Support for IVF Patients • FDA Blacklists Generics of Crushable OxyContin • Johnson & Johnson Reports Higher Revenue in Q1 with Help from Synthes Acquisition • A New Day at FDA Leads The Way For Sarepta Therapeutics • Wall Street Drops on Weak Chinese Economic Data, Multiple Explosions at Boston Marathon • Stocks Hold Thursday Gains as Dow and S&P Close on New Highs • ACADIA Pharmaceuticals Soars on Early Approval of Parkinson’s Treatment • Dow Hits New All-Time High as Stocks Hold on to Gains After Late Surge • Gilead Submits NDA to Food and Drug Administration for Oral Hepatitis C Treatment • Stocks Post Moderate Gains Ahead of Alcoa’s Earnings Report • AstraZeneca Rheumatoid Arthritis Drug Fails to Meet Both Primary Endpoints • Wall Street Holds on to Modest Gains with Increase in Jobless Claims, Japanese Stimulus Program • Court Reverses $482 Million Infringement Case Against J&J’s Cordis • Wall Street Slips on ADP Report Ahead of Friday’s Jobs Numbers • Wall Street Jumps as Private Health Insurance is Spared by Federal Government • Best Performers During the Dow and S&P 500's Record-Breaking Run in Q1 • Shares of Repros Therapeutics Up on Low Testosterone Drug Trials • FDA Again Rejects United Therapeutics’ NDA for Pulmonary Arterial Hypertension ER Tablet • U.S. Markets Bounce Back as Bernanke Backs Status Quo on Stimulus • Model N Soars Over 30 percent on IPO • Affymax to Fire 75 Percent of Employees as Share Nosedive • 5 Stocks That Turned Into Five-Baggers Over the Last Year • Ligand Pharma Partners with Spectrum Pharma, Lifts Outlook • Spectrum Pharmaceuticals Forecast for Fusilev Sales Slashed, Shares Nosedive • Apple Looks To Intel as Alternative To Samsung, and Top 5 Small Cap Stocks Ahead Of The Bell • Profiting on the Possibility That the FDA Has Turned a New Leaf • Ahead of the Bell: Pandora, Skullcandy, Texas Instruments, and Herbalife • Dow Soars to New All-Time High with Nearly All Components Trading in the Green • Shares of Acura Pharmaceuticals On the Run as Kerr Drugs as Nexafed to Locations • Is Clovis Oncology Riding a Biotech Bull? • Thoughts from the Frontline: The Healthcare Blues • Affymax Shares Approach the Abyss with Anemia Drug Recall • Royalty Pharma Makes $6.5 Billion Offer for Elan Corp. • FDA Rejects Dynavax’s Heplisav Hepatitis B Vaccine Citing Safety Concerns • EDAP TMS Jumps on Cancer Study Success • BlackBerry Gets Downgraded to Sell Along With Host of Other Stocks • WebMD Keeps the Doctor Away with Strong Earnings Report • Why Did CombiMatrix Spike Up Over 165 Percent Today? • Herbalife: The Saga Continues... • Marriott, Herbalife, Dell and BHP Making Headlines • Novogen Leaps on News of Successful Anti-Cancer Stem Cell Breakthrough • Novartis Cancels Exiting Chairman’s $78 Million Severance Pay • Momentum Stock Entry Signals Part 1 • Icahn Goes to Bat for Herbalife • StemCells Surges on Completed Clinical Trial for Treatment of Spinal Cord Injuries • Sanofi to Boost Stake in Regeneron • FDA Says No to Novo Nordisk’s New Insulin Products • As Sam Sees It: Why January's Best Performers Are Likely to Continue in 2013 • CVS Caremark Posts Record Quarterly and Full Year Revenue, Lifts 2013 Guidance • Stocks for 2013: Will These Hot Starters Be Good All Year? • Downgrades Hit Merck, Google, Chevron, Anheuser, Wal-Mart and More • More Drama for Herbalife as Report of FTC Probe Raises More Questions • Shares of Celsion Nosedive 80 Percent on Liver Cancer Trial Missing Primary Endpoint • AstraZeneca Tops Analysts Expectations, Warns of Sliding Sales in 2013 • Big Earnings, Economic Data on Tap Thursday

Life Sciences Company Profiles (OTCQB: TAUG) (NASDAQCM: DARA) (NASDAQCM: GALT) (NYSE AMEX: SYN)    Additional References Glossary of Healthcare Terms Healthcare News    Life Sciences Contributors David Leichtman is a partner in the trial practice of the New York office of Robins, Kaplan, Miller & Ciresi L.L.P. (read more...)